Retrieve available abstracts of 111 articles: HTML format
Single Articles
May 2025
HWANG HH, Yoo JS, Je JH, Lee HC, et al SH003 Inhibits Proliferation and Induces Apoptosis in NSCLC Cell Lines by
Inhibiting the Receptor Tyrosine Kinase-related Pathway.
Anticancer Res. 2025;45:1981-1995. PubMedAbstract available
PROBST E, Idel C, Fleckner J, Plotze-Martin K, et al Elevated PD-L1 Expression on Circulating Classical Monocytes Upon Checkpoint
Inhibitor Therapy Is Associated With Increased Plasma Interleukin 5 in Patients
With Lung Cancer.
Anticancer Res. 2025;45:1915-1925. PubMedAbstract available
ASANO Y, Han Q, Mizuta K, Kang BM, et al Recombinant Methioninase and Cisplatinum Act Synergistically to Inhibit Lewis
Lung Carcinoma Cells But Not Normal Fibroblasts.
Anticancer Res. 2025;45:1871-1876. PubMedAbstract available
DICKE J, Hero L, Kuhl S, Goldbrunner R, et al Expression of YAP1 and TAZ in Melanoma-, Bronchial- and Breast Carcinoma Brain
Metastasis: Primary vs. Relapsed Tumors.
Anticancer Res. 2025;45:1807-1812. PubMedAbstract available
TSUKAMOTO YO, Ohtsuka T, Yamauchi Y, Mun M, et al Efficacy and Prognostic Factors of Surgical Resection for Pulmonary Metastases
From Ovarian Cancer.
Anticancer Res. 2025;45:2071-2078. PubMedAbstract available
April 2025
AMPIL F, Previgliano C, Heath K, Bozeman A, et al Does Aggressive Versus Less Aggressive Non-operative Treatment of Large and Very
Large (>/=7 cm) Lung Cancers Matter?
Anticancer Res. 2025;45:1593-1598. PubMedAbstract available
MATSUDA H, Ikeda J, Ogasawara-Nosoko M, Endo M, et al Contrasting Role of COMMD5 in Renal Cell Carcinoma: Tumor Suppression and
Metastatic Enhancement.
Anticancer Res. 2025;45:1373-1385. PubMedAbstract available
FUTAWATARI N, Fukuyama T, Akimoto Y, Maehara J, et al Association Between Kita-kyushu Lung Cancer Antigen-1 Expression in Gastric
Cancer and Helicobacter pylori-infection Status.
Anticancer Res. 2025;45:1599-1606. PubMedAbstract available
ZHOU Y, Khawkhiaw K, Thithuan K, Saengboonmee C, et al Activation of the gamma-Aminobutyric Acid Receptor Type B Suppresses the
Proliferation of Lung Adenocarcinoma Cells.
Anticancer Res. 2025;45:1513-1523. PubMedAbstract available
TANIGUCHI Y, Tamiya A, Kamiyama Y, Sumitani H, et al Real-world Data of the Lung Cancer Compact Panel in Non-small Cell Lung Cancer
Using Tissue Samples.
Anticancer Res. 2025;45:1607-1615. PubMedAbstract available
March 2025
TONE M, Isono T, Yamamoto Y, Takeda Y, et al Peripheral CD4(+) T Cells Predict T Cell Immunity in Lung Tissues of Non-small
Cell Lung Cancer Patients.
Anticancer Res. 2025;45:909-920. PubMedAbstract available
WATANABE H, Nakamura S, Imamura Y, Okado S, et al Impact of Postoperative Therapy on Survival Outcomes in Non-small Cell Lung
Cancer Patients With Microscopic Residual Disease.
Anticancer Res. 2025;45:1193-1204. PubMedAbstract available
YUI M, Nakamura S, Koike Y, Hirota K, et al Efficacy of Molecular-targeted Agents in Vertebral Metastasis Management in
Non-small Cell Lung Cancer.
Anticancer Res. 2025;45:1105-1115. PubMedAbstract available
February 2025
MATSUKIDA A, Imai H, Shiono A, Ryuno Y, et al Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients
With Relapsed Limited Disease Small-cell Lung Cancer.
Anticancer Res. 2025;45:733-741. PubMedAbstract available
TAN XT, Huang SW, Lin YC, Lin FY, et al A New PD-L1 Nanobody Enhances Cell Death in Lung Cancer In Vitro and In Vivo.
Anticancer Res. 2025;45:535-547. PubMedAbstract available
KOH YW, Han JH, Haam S, Lee HW, et al Immunosuppressive State May Lead to Brain Metastases in Lung Squamous Cell
Carcinoma: Gene Expression and Immunohistochemical Analysis.
Anticancer Res. 2025;45:525-534. PubMedAbstract available
MOTOYAMA M, Shigefuku R, Tanaka N, Nishizawa M, et al Acyclic Retinoid Inhibits the EGFR/AKT Signaling Pathway and Cancels
Cisplatin-resistant Cell Characteristics.
Anticancer Res. 2025;45:433-443. PubMedAbstract available
January 2025
KAWAMURA H, Imaizumi T, Miyakawa T, Nakao E, et al Development of a Prognostic Model for Stage IV Colorectal Cancer Using Metastatic
Patterns.
Anticancer Res. 2025;45:341-350. PubMedAbstract available
IMPROTA G, Vita G, Tartarone A, Calice G, et al EGFR Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor
Treatment?
Anticancer Res. 2025;45:335-340. PubMedAbstract available
YOSHIDA K, Watanabe K, Nishimura T, Ikushima H, et al Improvement in Survival in Patients With Advanced Non-small Cell Lung Cancer.
Anticancer Res. 2025;45:295-305. PubMedAbstract available
LEE JY, Kim JN, Cho SG Kisspeptin Retards Tumor Growth of Lewis Lung Carcinoma Cells Through p38
MAPK-mediated Senescence.
Anticancer Res. 2025;45:113-122. PubMedAbstract available
YAMAUCHI K, Komuta R, Tanabe H, Yokoyama M, et al Real-world Outcomes of Durvalumab Consolidation in Elderly Patients With
Unresectable NSCLC Following CCRT With Daily Low-dose Carboplatin.
Anticancer Res. 2025;45:369-378. PubMedAbstract available
December 2024
TSURUOKA K, Tamura Y, Shimazu Y, Arai M, et al Association Between PD-L1 Expression and Efficacy of Chemoimmunotherapy in
Extensive-stage Small Cell Lung Cancer.
Anticancer Res. 2024;44:5531-5539. PubMedAbstract available
FUJIWARA M, Mimae T, Kushitani K, Tsubokawa N, et al Mitochondrial Metabolism as a Potential Novel Therapeutic Target for Lung
Adenocarcinoma.
Anticancer Res. 2024;44:5241-5252. PubMedAbstract available
TANIGUCHI Y, Shigenobu T, Hayashi A, Hirahara A, et al Optimal Therapy for Postoperative Recurrence: Does Salvage Radiation Work for
Locoregional Recurrence?
Anticancer Res. 2024;44:5541-5549. PubMedAbstract available
WEI L, Jiang Z, Chen S, Xia N, et al Pseudogene KRT17P3 Promotes NSCLC Progression Through Mir-338-3p/USP7/C-Myc.
Anticancer Res. 2024;44:5405-5423. PubMedAbstract available
DE MORAES FCA, Souza MEC, DA Silva ER, Kreuz M, et al Impact of ABCG2 rs2231142(421C>A) Variant on the Clinical Outcomes of Patients
With EGFR-mutated Non-small Cell Lung Cancer Treated With Gefitinib: A
Comprehensive Meta-analysis.
Anticancer Res. 2024;44:5361-5370. PubMedAbstract available
HAYASHI A, Kamio K, Miyanaga A, Yoshida K, et al Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through
Modulation of ABCB1 in Non-small Cell Lung Cancer.
Anticancer Res. 2024;44:5271-5282. PubMedAbstract available
CANON V, Lopez-Guerra JL, Arteagoitia A, Del Hoyo O, et al Impact of Radiation Dose on the Survival of Patients With Non-small Cell Lung
Cancer Treated With Palliative Intent: Results of a Multicenter Prospective
Study.
Anticancer Res. 2024;44:5477-5484. PubMedAbstract available
TEGENBOSCH C, Vekens K Recurrence Risk and Its Impact on Current Treatment Strategies in Early and
Locally Advanced NSCLC.
Anticancer Res. 2024;44:5495-5500. PubMedAbstract available
November 2024
SHOJI F, Minemura A, Kozuma Y, Nouno T, et al A Prospective Observational Study Analyzing the Diversity and Specific
Composition of the Oral and Gut Microbiota in Lung Cancer Patients.
Anticancer Res. 2024;44:5067-5080. PubMedAbstract available
NASER S, Schulz M, Schuchart S, VON Hammerstein-Equord A, et al Metabolomic Profiling of Large Extracellular Vesicles in Patients Suffering from
Small Cell Lung Cancer.
Anticancer Res. 2024;44:4729-4735. PubMedAbstract available
NAKASHIMA K, Umeda Y, Demura Y, Yamaoka K, et al Long-term Responders to Nanoparticle Albumin-bound Paclitaxel Following Immune
Checkpoint Inhibitor in Non-small Cell Lung Cancer.
Anticancer Res. 2024;44:5105-5111. PubMedAbstract available
VEHLOW A, Lange I, Lagies S, Kammerer B, et al Cytotoxic and Radiosensitizing Effects of European and African Propolis in 3D
Lung Carcinoma Cell Cultures.
Anticancer Res. 2024;44:4801-4811. PubMedAbstract available
KUO LK, Fu YK, Yeh CC, Lee CY, et al Combined Treatment of Caffeic Acid Phenethyl Ester With Docetaxel Inhibits
Survival of Non-small-cell Lung Cancer Cells via Suppression of c-MYC.
Anticancer Res. 2024;44:4915-4928. PubMedAbstract available
SUNG KS, Han SJ, Lee J, Kwon M, et al Identification of Plasma Protein Biomarkers for Predicting Lung Cancer.
Anticancer Res. 2024;44:5147-5155. PubMedAbstract available
JEON M, Yoo S, Park S, Choi Y, et al Over-expression of Transmembrane Protein 158 Predicts Aggressive Tumor Behavior
and Poor Prognosis in Lung Cancer.
Anticancer Res. 2024;44:4885-4893. PubMedAbstract available
NGUYEN TQ, Nguyen DH, Phan UTT, Tran PTT, et al Fenbendazole and Diisopropylamine Dichloroacetate Exert Synergistic Anti-cancer
Effects by Inducing Apoptosis and Arresting the Cell Cycle in A549 Lung Cancer
Cells.
Anticancer Res. 2024;44:4761-4772. PubMedAbstract available
SUZUKI Y, Maeno K, Kagawa Y, Sone K, et al Association of Plasma Nestin With Response to Immune Checkpoint Inhibitors
Combined With Chemotherapy in Extensive-stage Small-cell Lung Cancer: A Pilot
Study.
Anticancer Res. 2024;44:5095-5104. PubMedAbstract available
October 2024
NATHANI A, Khan I, Tanimoto MH, Mejia JAA, et al Antitumor Potential of Guttiferone E Combined With Carboplatin Against
Osimertinib-resistant H1975 Lung Cancer Through Apoptosis.
Anticancer Res. 2024;44:4175-4188. PubMedAbstract available
TSUKAGUCHI A, Tamiya A, Fukuda S, Iwahashi Y, et al Safety and Efficacy of Durvalumab After Chemoradiotherapy in Antinuclear
Antibody-positive Patients With Non-small Cell Lung Cancer.
Anticancer Res. 2024;44:4517-4524. PubMedAbstract available
ASANO Y, Yamamoto N, Hayashi K, Takeuchi A, et al Serum Inflammatory Dynamics as Novel Biomarkers for Immune Checkpoint Inhibitors
in Non-small-cell Lung Cancer With Bone Metastases.
Anticancer Res. 2024;44:4493-4503. PubMedAbstract available
KIM HJ, Kim DY Potential Anti-tumor Properties of PDIA4 in Lung Adenocarcinoma.
Anticancer Res. 2024;44:4309-4315. PubMedAbstract available
CHOI YJ, Ramos SC, Sim HB, Han JY, et al Promising Approach for Optimizing In Vivo Fluorescence Imaging in a Tumor Mouse
Model: Precision in Cancer Research.
Anticancer Res. 2024;44:4347-4358. PubMedAbstract available
KURIBAYASHI K, Hirano J True Benefits of Immune Checkpoint Inhibitors in the Treatment of Malignant
Pleural Mesothelioma in Japan.
Anticancer Res. 2024;44:4135-4145. PubMedAbstract available
KWON M, Lim D, Park J, Gil W, et al MiR-140-3p Improves Sensitivity to Docetaxel by Suppressing PD-L1/ABCG2/MVP
Expression in Lung Adenocarcinoma.
Anticancer Res. 2024;44:4283-4299. PubMedAbstract available
LIN PJ, Kuo YC, Hu PW, Chen WL, et al Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung
Cancer Xenograft Models.
Anticancer Res. 2024;44:4327-4337. PubMedAbstract available
KIM I, Choi SH, Lee SY, Yoo SS, et al PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant
NSCLC.
Anticancer Res. 2024;44:4505-4516. PubMedAbstract available
September 2024
SONG HJ, Sharma S, Kim T, Kim YH, et al Macrophage-induced Expression of TonEBP/NFAT5 Is Associated With Gefitinib
Resistance and Migration in PC-9 Cells.
Anticancer Res. 2024;44:3867-3874. PubMedAbstract available
CHEN HJ, Cheng WC, Chen CH, Tu CY, et al Efficacy of Respiration-controlled Radiotherapy Among Patients With Locally
Advanced-stage Lung Cancer: A Population-based Study.
Anticancer Res. 2024;44:4093-4100. PubMedAbstract available
SAGIE N, Romanov E, Kezerle Y, Meirovitz A, et al Expression Analysis of SSTR 1, 2 and 3 in Small-cell Lung Cancer Patients as
Targets for Future Peptide Receptor Radionuclide Therapy.
Anticancer Res. 2024;44:3807-3812. PubMedAbstract available
TAKEDA K, Kikuchi Y, Sawada YU, Kumamoto T, et al Simultaneously Detected Liver and Lung Metastases from Colorectal Carcinoma: A
Potential Treatment Strategy.
Anticancer Res. 2024;44:3945-3954. PubMedAbstract available
HAYASHI K, Ishikawa H, Fujiwara K, Nakai M, et al Stereotactic Ablative Radiotherapy for Early-stage Lung Cancer in Patients With
Left Ventricular Assist Device: A Case Series.
Anticancer Res. 2024;44:4113-4117. PubMedAbstract available
August 2024
URAMOTO H, Motono N, Iijima Y, Nakajima Y, et al Long-term Outcomes of Salvage Surgery Versus Induction Therapy Followed by
Surgical Resection for Advanced NSCLC: A Propensity Score-matched Analysis.
Anticancer Res. 2024;44:3525-3531. PubMedAbstract available
ARICO D, Macri P, Bambaci M, Leone G, et al Non-palpable Pulmonary Nodules and Uniportal-VATS: Radio-guided Localization
(ROLL) Experience of a Lung Multidisciplinary Team.
Anticancer Res. 2024;44:3507-3514. PubMedAbstract available
IMAMURA Y, Kato T, Nomata Y, Okado S, et al Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type
EGFR Non-Small Cell Lung Cancer.
Anticancer Res. 2024;44:3451-3461. PubMedAbstract available
NOHIRA S, Kuramitsu S, Ohno M, Fujita M, et al Tertiary Lymphoid Structures in Brain Metastases of Lung Cancer: Prognostic
Significance and Correlation With Clinical Outcomes.
Anticancer Res. 2024;44:3615-3621. PubMedAbstract available
July 2024
OHGURI T, Morisaki T, Itamura H, Tani S, et al Prophylactic Effect of Clarithromycin on Radiation Pneumonitis in IMRT for Lung
Cancer.
Anticancer Res. 2024;44:2989-2995. PubMedAbstract available
LUUKKAINEN MEK, Koivunen JP ALK Inhibitor and Chemotherapy Combinations in Models of ALK-Translocated NSCLC.
Anticancer Res. 2024;44:2805-2813. PubMedAbstract available
ZO S, Kim C, Lee HY, Park G, et al Comparative Analysis of Clinical Characteristics and Prognosis Between Primary
Lung Cancers Identified as Screening Detected and Incidentally Detected Pulmonary
Nodules.
Anticancer Res. 2024;44:3163-3173. PubMedAbstract available
IGATA F, Inoue H, Ikeda T, Nakao A, et al Comparison of Real-world Efficacy and Safety of Atezolizumab and Durvalumab in
Combination With Chemotherapy for First-line Treatment of Extensive-stage
Small-cell Lung Cancer.
Anticancer Res. 2024;44:3175-3183. PubMedAbstract available
EBI N, Inoue H, Igata F, Okuma R, et al Clinical Association Between Immune-related Adverse Events and Treatment Efficacy
in Patients With Non-small-cell Lung Cancer Treated With
Nivolumab-Ipilimumab-based Therapy.
Anticancer Res. 2024;44:3087-3095. PubMedAbstract available
June 2024
SWITLIK W, Wyzewski Z, Gregorczyk-Zboroch K, Gietler M, et al Deciphering the Role of miR-30a-5p and DLGAP1 Gene in Non-small Cell Lung Cancer.
Anticancer Res. 2024;44:2445-2451. PubMedAbstract available
ANO S, Kikuchi N, Okauchi S, Numata T, et al Real Clinical Practice of Combined Atezolizumab Plus Chemotherapy in Patients
With Small Cell Lung Cancer.
Anticancer Res. 2024;44:2725-2730. PubMedAbstract available
ENDO K, Tanaka H, Matsuo H, Onoda T, et al Adverse Event Profile of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel
Combination Therapy Based on JADER.
Anticancer Res. 2024;44:2653-2660. PubMedAbstract available
SEO HR, Kim HJ, Ryu H, Song JY, et al Ionizing Radiation-treated NRF2-deficient Cancer Cells Promote Type I Interferon
Signaling in Immune Cells.
Anticancer Res. 2024;44:2577-2585. PubMedAbstract available
PARK JS, Park HY, Choi Y Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission
Tomography/Computed Tomography in Lung Cancer.
Anticancer Res. 2024;44:2681-2687. PubMedAbstract available
May 2024
SOLIS-ESTRADA J, Arredondo-Espinoza E, Pioquinto-Avila E, Gonzalez-Cruz AO, et al Design and Evaluation of a Humanized Anti-EGFR huscFv Antibody Fragment in
Combination With Metformin in A549 Cells In Vitro.
Anticancer Res. 2024;44:1955-1962. PubMedAbstract available
CHEN LH, Tsai YF, Wu WT, Chiu KL, et al Association of Matrix Metalloproteinase-9 Genotypes With Lung Cancer Risk in
Taiwan.
Anticancer Res. 2024;44:1845-1852. PubMedAbstract available
RADES D, Cremers F, Janssen S, Bartscht T, et al Associations Between Mean Lung Dose and Prevalence of Radiation Pneumonitis in
Elderly Lung Cancer Patients.
Anticancer Res. 2024;44:2073-2079. PubMedAbstract available
CHOI YJ, Chung YH, Lee K, Jeong M, et al SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring
BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway.
Anticancer Res. 2024;44:1905-1913. PubMedAbstract available
JI N, Lee Y, Lee SH, Kim HS, et al Diagnostic Value of Immunostaining for Thyroid Transcription Factor 1 (TTF1) and
Paired Box 8 (PAX8) in Distinguishing Pulmonary Metastases of Mesonephric and
Mesonephric-like Adenocarcinomas from Primary Lung Adenocarcinomas.
Anticancer Res. 2024;44:2159-2170. PubMedAbstract available
CHARPIDOU A, Mani M, Kokkotou E, Stournara L, et al Molecular Diagnostics and Treatment Patterns in Metastatic Non-small Cell Lung
Cancer Patients: Real World Evidence from Greece: LACHESIS Study.
Anticancer Res. 2024;44:2063-2072. PubMedAbstract available
KOH YW, Han JH, Haam S, Lee HW, et al Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles
Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell
Carcinoma.
Anticancer Res. 2024;44:2081-2089. PubMedAbstract available
April 2024
MAEZAWA Y, Taguchi M, Kawakami T, Inui T, et al Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter
Retrospective Study.
Anticancer Res. 2024;44:1751-1757. PubMedAbstract available
CHIU KL, Wang SC, Li CH, Shen TC, et al The Contribution of Double-strand Break Repair Radiation Sensitive Protein 51
Genotypes to Lung Cancer in Taiwan.
Anticancer Res. 2024;44:1409-1416. PubMedAbstract available
HASHIMOTO K, Kaira K, Imai H, Miura YU, et al Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1
Blocker in Extensive Stage Small Cell Lung Cancer.
Anticancer Res. 2024;44:1541-1551. PubMedAbstract available
March 2024
INOMATA M, Minatoyama S, Takata N, Hayashi K, et al Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer
Ineligible for Platinum Doublet Chemotherapy.
Anticancer Res. 2024;44:1241-1245. PubMedAbstract available
KINOSHITA H, Kinoshita S, Kamoda H, Hagiwara Y, et al Combined Auranofin and Celecoxib Suppresses the Local Progression and Pulmonary
Metastases of Osteosarcoma In Vivo.
Anticancer Res. 2024;44:1045-1049. PubMedAbstract available
YOSHIDA C, Kadota K, Ibuki E, Ishikawa R, et al Siglec10 Expression on Tumor-associated Macrophages Is an Independent Prognostic
Factor in Stage I Lung Adenocarcinoma.
Anticancer Res. 2024;44:1289-1297. PubMedAbstract available
February 2024
NATSUME K, Ye J, Mukai Y, Yamakawa K, et al Discrepancies Between Morphological and Immunohistochemical Classifications Are
Associated With Prognoses and Subtypes of Lung Cancer.
Anticancer Res. 2024;44:711-722. PubMedAbstract available
TRINH JQ, Xiong Y, Smith LM, Abughanimeh O, et al Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution
Study.
Anticancer Res. 2024;44:605-612. PubMedAbstract available
KANASAKI H, Ozawa Y, Nakamura N, Nagasaki K, et al Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small Cell
Lung Cancer.
Anticancer Res. 2024;44:723-730. PubMedAbstract available
KURIHARA S, Nakamura R, Yoneyama S, Takase S, et al Prognostic Impact of Preoperative Assessment of Muscle Mass and Strength in
Surgically Resected Lung Cancer.
Anticancer Res. 2024;44:767-779. PubMedAbstract available
NAKAO M, Kinoshita R, Kuriyama M, Kiyotoshi H, et al Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell
Lung Cancer.
Anticancer Res. 2024;44:845-851. PubMedAbstract available
CHECK JH, Check DL, DO TP, Srivastava M, et al Significant Palliative Benefits Following Therapy With Mifepristone for Advanced
Treatment Resistant Small Cell Lung Cancer.
Anticancer Res. 2024;44:659-664. PubMedAbstract available
MATSUMOTO T, Toya R, Shimohigashi Y, Yamaguchi K, et al Influence of Respiratory Motion on Dose Distribution in Gastric Mucosa-associated
Lymphoid Tissue Lymphoma Radiotherapy.
Anticancer Res. 2024;44:687-694. PubMedAbstract available
BARUT Z, Akdeniz FT, Isbir T Investigation of Mirna-223-3p Expression in Non-small Cell Lung Cancers.
Anticancer Res. 2024;44:585-591. PubMedAbstract available
HONG JM, Jeong BK, Han D, Kim K, et al CCR10-mediated Enhancement of T Cell Trafficking for Improved Tumor
Immunotherapy.
Anticancer Res. 2024;44:521-532. PubMedAbstract available
January 2024
NIEDER C, Aanes SG, Dalhaug A, Haukland EC, et al Sex Differences in Presentation, Treatment, and Survival in Patients Receiving
Palliative (Chemo)Radiotherapy for Non-Small Cell Lung Cancer.
Anticancer Res. 2024;44:301-305. PubMedAbstract available
CHEN PM, Huang YH, Chen HH, Chu PY, et al Catalase Expression Is an Independent Prognostic Marker in Lung Adenocarcinoma.
Anticancer Res. 2024;44:287-300. PubMedAbstract available
TATE MK, Hernandez M, Chang JY, Lin SH, et al Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small
Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial.
Anticancer Res. 2024;44:133-137. PubMedAbstract available
MOSER SS, Apter L, Solomon J, Chodick G, et al Time on Treatment and Survival Outcomes for Patients Treated With First-line
Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive
Metastatic Non-small Cell Lung Cancer: Real-world Experience Data.
Anticancer Res. 2024;44:257-265. PubMedAbstract available
December 2023
AGOLLI L, Eroglu Z, Nicosia L, Habermehl D, et al Dosimetric Parameters After VMAT Adaptive Radiotherapy in Patients With Locally
Advanced NSCLC Undergoing 4DCT.
Anticancer Res. 2023;43:5573-5582. PubMedAbstract available
LEE HH, Hsieh CC, Chang CC, Liao WT, et al YTHDF3 Modulates EGFR/ATK/ERK/p21 Signaling Axis to Promote Cancer Progression
and Osimertinib Resistance of Glioblastoma Cells.
Anticancer Res. 2023;43:5485-5498. PubMedAbstract available
KIMURA N, Kadota K, Ibuki E, Ishikawa R, et al (Pro)renin Receptor Down-regulation Is Associated With a Higher Risk of
Recurrence in Lung Adenocarcinoma.
Anticancer Res. 2023;43:5671-5680. PubMedAbstract available
TONG X, Zhang R, Sun R, Yang W, et al Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance
in the Non-small Cell Lung Cancer Cell Line H1975.
Anticancer Res. 2023;43:5459-5474. PubMedAbstract available
ENDO I, Amatya VJ, Kushitani K, Nakagiri T, et al Long Non-coding RNA LINC00152 Requires EZH2 to Promote Mesothelioma Cell
Proliferation, Migration, and Invasion.
Anticancer Res. 2023;43:5367-5376. PubMedAbstract available
LIU B, Pu ZY, Wang L, Fang J, et al Inhibiting miR-33b-5p Enhances Chemoresistance in Lung Adenocarcinoma by
Targeting YWHAH to Regulate Epithelial-mesenchymal Transition.
Anticancer Res. 2023;43:5447-5458. PubMedAbstract available
LIN HW, Shih TW, Amanna A, Chang MS, et al PHRF1 Promotes Cell Invasion by Modulating SOX4 Expression in Colorectal Cancer
HCT116-p53(-/-) Cells.
Anticancer Res. 2023;43:5437-5446. PubMedAbstract available
ZHANG XW, Mohr J, Halama N, Koschny R, et al Analysis of an Unselected Patient Cohort With Advanced Colorectal Carcinoma from
a Maximum Care Center.
Anticancer Res. 2023;43:5589-5596. PubMedAbstract available
November 2023
ITO S, Tsurumi K, Shindo N, Soma S, et al Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in
Patients With EGFR-mutated Lung Adenocarcinoma.
Anticancer Res. 2023;43:5031-5040. PubMedAbstract available
SAKAI K, Kuramoto J, Takahashi T, Kawano Y, et al Impact of Locoregional Therapies for Brain Lesions on Survival in Patients With
Non-small Cell Lung Cancer With Multiple Extrathoracic Metastases.
Anticancer Res. 2023;43:5107-5114. PubMedAbstract available
ITO A, Tarukawa T, Suzuki Y, Sakaguchi T, et al Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in
Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma.
Anticancer Res. 2023;43:5197-5204. PubMedAbstract available
YANG T, Si Q, Liu M, DU R, et al Novel Biomarker miRNA-625-3p Promotes Cell Proliferation and Metastasis of Lung
Adenocarcinoma by Targeting KLF9.
Anticancer Res. 2023;43:4923-4935. PubMedAbstract available
MATSUDO K, Takenaka T, Hashinokuchi A, Nagano T, et al Impact of Chronic Obstructive Pulmonary Disease on the Long-term Prognosis of
Patients Undergoing Lobectomy for Non-small-cell Lung Cancer: A Propensity
Score-matched Analysis.
Anticancer Res. 2023;43:5215-5222. PubMedAbstract available
ISOYAMA-SHIRAKAWA Y, Yoshitake T, Ninomiya K, Asai K, et al Combination of Clinical Factors and Radiomics Can Predict Local Recurrence and
Metastasis After Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer.
Anticancer Res. 2023;43:5003-5013. PubMedAbstract available
October 2023
TAMURA T, Numata T, Yanai H, Nakamura R, et al Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation
Study in Ibaraki Group (ATTENTION-IBARAKI).
Anticancer Res. 2023;43:4583-4591. PubMedAbstract available
SAWABATA N, Morita K, Tatsumi S, Fujii T, et al A Novel Filtration Membrane for Clustered Circulating Tumor Cell Extraction: A
Prospective Feasibility Study.
Anticancer Res. 2023;43:4683-4690. PubMedAbstract available
NAGAMINE H, Yashiro M, Yoshimoto N, Izumi M, et al RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With
Low PD-L1 Expression.
Anticancer Res. 2023;43:4663-4672. PubMedAbstract available
ZHAO QI, Ren W, Gao S, Mu N, et al Immune Cell Infiltration and Clinical Significance of Angiogenesis-related Genes
in Lung Adenocarcinoma.
Anticancer Res. 2023;43:4473-4489. PubMedAbstract available